Kent D Taylor

USPTO Granted Patents = 15 (Patent Applications = 31)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 107(Granted Patents)

Location History:

Santa Paula, CA (US) (2001 - 2002)
Ventura, CA (US) (2006 - 2024)

Company Filing History:

15 out of 596

Cedars-sinai Medical Center

patents

1 out of 580

The Uab Research Foundation

patents

1 out of 15,458

University of California

patents

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12110555 - Diagnosis and treatment of inflammatory bowel disease (2024-10-08),

2. 12084722 - Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease (2024-09-10),

3. 11268149 - Diagnosis and treatment of inflammatory bowel disease (2022-03-08),

4. 11236393 - Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease (2022-02-01),

5. 10544459 - Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease (2020-01-28),

6. 9580752 - Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy (2017-02-28),

7. 9305137 - Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach (2016-04-05),

8. 8178294 - Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes (2012-05-15),

9. 8153443 - Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease (2012-04-10),

10. 7790370 - Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease (2010-09-07),

11. 7419782 - Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease (2008-09-02),

12. 7141373 - Method of haplotype-based genetic analysis for determining risk for developing insulin resistance and coronary artery disease (2006-11-28),

13. 6376176 - Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease (2002-04-23),

14. 6348316 - Genetic testing for determining the risk of pouchitis development (2002-02-19),

15. 6297014 - Genetic test to determine non-responsiveness to statin drug treatment (2001-10-02),

Title: Kent D. Taylor: Pioneer in Inflammatory Bowel Disease Research

Introduction

Kent D. Taylor, located in Ventura, CA, is an accomplished inventor with a remarkable portfolio of 15 patents. His innovations focus primarily on the diagnosis and treatment of inflammatory bowel disease (IBD), offering groundbreaking insights into this critical health issue.

Latest Patents

Among his latest contributions, Kent has developed innovative methods for diagnosing and predicting susceptibility to inflammatory bowel diseases such as Crohn's disease and Ulcerative Colitis. One notable patent involves identifying genetic variants, including NOD2, TLR8, TLR2, CARD8, CARD15, and JAK3 to assess susceptibility and disease progression in individuals. Additionally, he has pioneered methods using serological markers to evaluate responsiveness to anti-TNFα therapy, providing a significant advancement in personalized treatment plans for patients suffering from IBD.

Career Highlights

Kent's professional journey includes significant roles at reputable institutions, such as Cedars-Sinai Medical Center and the UAB Research Foundation. His work has led to pivotal advancements in understanding the genetic and serological underpinnings of IBD, positioning him as a leader in this essential field of research.

Collaborations

Throughout his career, Kent has collaborated with esteemed colleagues, including Jerome I. Rotter and Stephan R. Targan. These partnerships have enriched his research efforts and contributed to the successful development of his innovative patents.

Conclusion

In summary, Kent D. Taylor stands out as a notable inventor whose work in inflammatory bowel disease has the potential to transform diagnostic and treatment methodologies. His dedication to advancing medical science is evident through his impressive array of patents and collaborations with other leading experts in the field.

This text is generated by artificial intelligence and may not be accurate.